For example, prevalent detection of BCR-ABL1 fusions in CML cases may be useful in prescribing tyrosine kinase inhibitor (TKI) treatment regimens such as imatinib [6], while detection of PML-RARa fusions may require treatments designed to treat the M3 AML subtype, acute promyelocytic leukemia (APL) [7]. This evidence concerns the gene BCR and acute myeloid leukemia.